Business
-
Advanced Inhalation Therapies (AIT), which is developing inhaled nitric oxide therapies for cystic fibrosis and other indications, has filed a request to withdraw its registration statement for an initial public offering. The company announced its… Read more . . .
-
Smartinhaler maker Adherium has announced an upcoming $8 million AUD ($6 million USD) share placement to Fidelity International, increasing Fidelity’s holdings in the company to 10%. The shares will be issued on July 26, 2016.… Read more . . .
-
Windtree Therapeutics (formerly Discovery Laboratories) said that it has received an additional $1 million from a Phase 2 Small Business Innovation Research (SBIR) grant initially announced in October 2014. The grant, with a total potential… Read more . . .
-
Therapix Biosciences has entered into an agreement with the Hebrew University’s technology transfer company Yissum to obtain an exclusive worldwide license for an intranasal formulation of cannabinoids developed by Elka Touitou of the university’s Institute… Read more . . .
-
AeroVanc developer Savara Pharmaceuticals has acquired Serendex Pharmaceuticals, which is developing Molgradex inhaled granulocyte-macrophage colony-stimulating factor (molgramostim) for the treatment of autoimmune pulmonary alveolar proteinosis (PAP). Serendex announced in September 2015 that it was initiating… Read more . . .
-
In May 2016, Grupo Ferrer announced that it would acquire inhaled drug company Alexza Pharmaceuticals; as of June 21, 2016, the company says, Ferrer Pharma has merged into Alexza Pharmaceuticals, with Alexza now a wholly… Read more . . .
-
US generic inhalation solutions manufacturer Nephron Pharmaceuticals has licensed Apotex’s generic budesonide inhalation suspension, a generic version of AstraZeneca’s Pulmicort Respules, and subsequently launched the product in the US, the company said. Nephron will manufacture,… Read more . . .
-
MannKind Corporation has announced that it signed an agreement with JDRF (formerly the Juvenile Diabetes Research Foundation) to collaborate on research focused on the use of Afrezza inhaled insulin in pediatric diabetes patients. JDRF is… Read more . . .
-
California-based Innovus Pharmaceuticals announced that it has signed a manufacturing agreement for its FlutiCare fluticasone propionate nasal spray in anticipation of FDA approval, which it expects in the 3rd quarter of 2016. No details were… Read more . . .
-
Perrigo and Hikma subsidiary West-Ward Pharmaceuticals have launched an OTC fluticasone propionate nasal spray, a generic version of Flonase, in the US after receiving approval for the product from the FDA, the companies said. The… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden